Compare Stocks: CLLS, MLTX, MNKD, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.24 -2.4%	$3.03	$2.35 ▼ $5.48	$325.10M	2.92	17,293 shs	4,833 shs
IMTX Immatics	$9.56 +1.1%	$9.42	$5.67 ▼ $12.41	$1.31B	1.33	599,808 shs	497,159 shs
MLTX MoonLake Immunotherapeutics	$15.01 -1.2%	$17.80	$5.95 ▼ $62.75	$1.28B	1.04	1.39 million shs	1.43 million shs
MNKD MannKind	$4.06 +2.5%	$4.05	$2.23 ▼ $6.51	$1.31B	1.1	3.33 million shs	2.81 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	-2.41%	-4.71%	+16.13%	+5.88%	+25.10%
IMTX Immatics	+1.06%	+1.16%	-2.15%	-2.35%	+75.41%
MLTX MoonLake Immunotherapeutics	-1.18%	+0.13%	-14.47%	-16.15%	-74.77%
MNKD MannKind	+2.53%	+2.78%	-0.98%	+19.41%	-26.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.24 -2.4%	$3.03	$2.35 ▼ $5.48	$325.10M	2.92	17,293 shs	4,833 shs
IMTX Immatics	$9.56 +1.1%	$9.42	$5.67 ▼ $12.41	$1.31B	1.33	599,808 shs	497,159 shs
MLTX MoonLake Immunotherapeutics	$15.01 -1.2%	$17.80	$5.95 ▼ $62.75	$1.28B	1.04	1.39 million shs	1.43 million shs
MNKD MannKind	$4.06 +2.5%	$4.05	$2.23 ▼ $6.51	$1.31B	1.1	3.33 million shs	2.81 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	-2.41%	-4.71%	+16.13%	+5.88%	+25.10%
IMTX Immatics	+1.06%	+1.16%	-2.15%	-2.35%	+75.41%
MLTX MoonLake Immunotherapeutics	-1.18%	+0.13%	-14.47%	-16.15%	-74.77%
MNKD MannKind	+2.53%	+2.78%	-0.98%	+19.41%	-26.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	2.83	Moderate Buy	$7.00	116.05% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	115.48% Upside
MLTX MoonLake Immunotherapeutics	2.41	Hold	$24.57	63.70% Upside
MNKD MannKind	2.44	Hold	$8.39	106.72% Upside

Current Analyst Ratings Breakdown

Latest CLLS, MLTX, MNKD, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$14.00 ➝ $13.00
8/5/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $14.00
7/23/2026	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
7/17/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$56.58M	5.75	N/A	N/A	$0.41 per share	7.90
IMTX Immatics	$41.70M	31.33	N/A	N/A	$3.47 per share	2.76
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.03 per share	N/A
MNKD MannKind	$348.97M	3.74	$0.06 per share	64.00	($0.21) per share	-19.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	11/13/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)

Latest CLLS, MLTX, MNKD, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/7/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	1.61	1.37	1.37
IMTX Immatics	N/A	7.54	7.54
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
MNKD MannKind	N/A	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
IMTX Immatics	64.41%
MLTX MoonLake Immunotherapeutics	93.85%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
IMTX Immatics	3.30%
MLTX MoonLake Immunotherapeutics	10.40%
MNKD MannKind	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
IMTX Immatics	260	136.69 million	129.65 million	Optionable
MLTX MoonLake Immunotherapeutics	2	85.11 million	76.26 million	Optionable
MNKD MannKind	400	321.54 million	313.18 million	Optionable

CLLS, MLTX, MNKD, and IMTX Headlines

Recent News About These Companies

MannKind (NASDAQ:MNKD) Rating Lowered to "Strong Sell" at Zacks Research

September 5 at 7:59 AM | marketbeat.com

Wellington Management Group LLP Purchases 4,561,628 Shares of MannKind Corporation $MNKD

September 5 at 4:47 AM | marketbeat.com

Wells Fargo Remains a Buy on MannKind (MNKD)

September 3 at 3:08 PM | theglobeandmail.com

Braidwell LP Makes New Investment in MannKind Corporation $MNKD

September 3 at 4:39 AM | marketbeat.com

MannKind to Present at Upcoming Investor Conferences

September 2 at 8:30 AM | globenewswire.com

MannKind (NASDAQ:MNKD) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

September 2 at 1:39 AM | marketbeat.com

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

August 28, 2026 | zacks.com

MannKind Corporation $MNKD Shares Bought by Bank of America Corp DE

August 25, 2026 | marketbeat.com

MannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Moderate Buy" from Analysts

August 23, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?

August 22, 2026 | marketbeat.com

MannKind Prepares Shelf Registration for Potential Stock Offering

August 21, 2026 | tipranks.com

Research Analysts Set Expectations for MannKind Q3 Earnings

August 14, 2026 | marketbeat.com

MannKind FY2029 EPS Estimate Decreased by HC Wainwright

August 13, 2026 | marketbeat.com

MannKind: New Approvals Majorly Increase MannKind's Prospects

August 13, 2026 | seekingalpha.com

MannKind: New Approvals Majorly Increase MannKind's Prospects

August 13, 2026 | seekingalpha.com

Mannkind Corp

August 12, 2026 | money.usnews.com

Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock

August 10, 2026 | marketbeat.com

Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD

August 10, 2026 | marketbeat.com

First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD

August 9, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD

August 9, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, MLTX, MNKD, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

$3.24 -0.08 (-2.41%)

As of 09/4/2026 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Immatics NASDAQ:IMTX

$9.56 +0.10 (+1.06%)

As of 09/4/2026 04:00 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MoonLake Immunotherapeutics NASDAQ:MLTX

$15.01 -0.18 (-1.18%)

As of 09/4/2026 04:00 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MannKind NASDAQ:MNKD

$4.06 +0.10 (+2.53%)

As of 09/4/2026 04:00 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, MLTX, MNKD, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, MLTX, MNKD, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, MLTX, MNKD, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, MLTX, MNKD, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

Immatics NASDAQ:IMTX

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, MLTX, MNKD, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, MLTX, MNKD, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, MLTX, MNKD, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, MLTX, MNKD, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

Immatics NASDAQ:IMTX

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools